Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

ICU Medical, Inc.

US Class I Ongoing · initiated 2025-02-13

Labeling: Label Error on Declared Strength. Cases labeled POTASSIUM CHLORIDE 20 mEq, may contain flexible containers with overwrap mislabeled as 10 mEq. The cor…

Johnson, S C and Son, Inc

US Class II Ongoing · initiated 2025-02-13

Chemical Contamination

World Perfumes Inc.

US Class II Ongoing · initiated 2025-02-13

Defective Container: broken or leaking bottles.

Wuxi Medical lnstrument Factory Co., Ltd.

US Class II Ongoing · initiated 2025-02-12

Lack of assurance of sterility and cGMP deviations observed at the manufacturing site.

Nephron Sterile Compounding Center LLC

US Class II Terminated · initiated 2025-02-10

Lack of Assurance of Sterility: There is a potential for leakage at the IV bottle port.

Aspen Biopharma Labs Pvt., Ltd.

US Class II Ongoing · initiated 2025-02-07

CGMP Deviations

Aspen Biopharma Labs Pvt., Ltd.

US Class II Ongoing · initiated 2025-02-07

CGMP Deviations

Aspen Biopharma Labs Pvt., Ltd.

US Class II Ongoing · initiated 2025-02-07

CGMP Deviations

Aspen Biopharma Labs Pvt., Ltd.

US Class II Ongoing · initiated 2025-02-07

CGMP Deviations

Aspen Biopharma Labs Pvt., Ltd.

US Class II Ongoing · initiated 2025-02-07

CGMP Deviations

Aspen Biopharma Labs Pvt., Ltd.

US Class II Ongoing · initiated 2025-02-07

CGMP Deviations

Padagis US LLC

US Class II Completed · initiated 2025-02-06

Defective Container: Some packets may not be fully sealed, potentially allowing for loss of Ethanol from the product.

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2025-02-06

Failed Dissolution Specifications

BIOV Health Calcium (Carbonate) 300 mg Chewable Tablets

Canada Type II Ongoing · initiated 2025-02-06

Product quality. Verify if your product is affected.Stop taking the affected product and consult your healthcare provider for any health concerns.If you have an…

SENNA Tablet USP ; JAMP Senna ; Jamp - SENNA

Canada Type II Ongoing · initiated 2025-02-05

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

AvKARE

US Class II Ongoing · initiated 2025-02-04

Subpotent Drug: Out of Specification (OOS) result for De hydro Impurity (0.654%) for 18 M Stability sample and low assay 94.9% (specification of NLT 95.0% NMT 1…

Ferinject

Canada Type III Ongoing · initiated 2025-02-04

Labelling. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

Lacosamide Injection 10mg/ml

Canada Type I Ongoing · initiated 2025-02-03

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

Fagron Compounding Services

US Class II Completed · initiated 2025-01-31

Lack of Assurance of Sterility

Alvogen, Inc

US Class I Ongoing · initiated 2025-01-31

Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.

Direct Rx

US Class II Ongoing · initiated 2025-01-31

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

APO-QUETIAPINE XR

Canada Type I Ongoing · initiated 2025-01-31

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

PMS-FLUOXETINE 10 mg

Canada Type II Ongoing · initiated 2025-01-31

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories

US Class II Ongoing · initiated 2025-01-30

Failed Dissolution Specifications.

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-01-29

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.